AMGEN Inc(AMGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 5:12 PM ET (Korea 11/7 07:12)
Full metrics table
| Index | DJIA, NDX, S&P 500 | P/E | 26.7 | EPS (ttm) | 17.24 | Insider Own | 0.23% | Shs Outstand | 540.9M | Perf Week | -1.2% |
| Market Cap | 249.05B | Forward P/E | 18.43 | EPS next Y | 6.4% | Insider Trans | -0.81% | Shs Float | 539.7M | Perf Month | 13% |
| Enterprise Value | 289.86B | PEG | 2.63 | EPS next Q | 5.64 | Inst Own | 85.64% | Short Float | 2.48% | Perf Quarter | 10.36% |
| Income | 9.39B | P/S | 6.39 | EPS this Y | 7.48% | Inst Trans | -0.35% | Short Ratio | 4.81 | Perf Half Y | 38.81% |
| Sales | 38.98B | P/B | 17.35 | EPS next 5Y | 7% | ROA | 10.09% | Short Interest | 13.38M | Perf YTD | 40.67% |
| Book/sh | 26.53 | P/C | 18.88 | EPS past 3/5Y | 5.51% 2.93% | ROE | 78.35% | 52W High | -4.87% ($483.99) | Perf Year | 45.89% |
| Cash/sh | 24.38 | P/FCF | 25.99 | Sales past 3/5Y | 12.09% 7.79% | ROIC | 14.24% | 52W Low | 47.39% ($312.39) | Perf 3Y | 68.76% |
| Dividend Est. | $10.07 (2.19%) | EV/EBITDA | 15.79 | EPS Y/Y TTM | 33.48% | Gross Margin | 74% | Volatility(W/M) | 3.21% 2.55% | Perf 5Y | 115.38% |
| Dividend TTM | 9.94 | EV/Sales | 7.44 | Sales Y/Y TTM | 8.6% | Oper. Margin | 35.6% | ATR (14) | 12.8 | Perf 10Y | 240.04% |
| Dividend Ex-Date | 2026/11/20 | Quick Ratio | 1.2 | EPS Q/Q | 19.27% | Profit Margin | 24.09% | RSI (14) | 60.47 | Recom | 2.68 |
| Dividend Gr. 3/5Y | 7.05% 8.27% | Current Ratio | 1.48 | Sales Q/Q | 8.1% | SMA20 | 3.36% ($445.45) | Beta | 0.42 | Target Price | $436.68 |
| Payout | 66.92% | Debt/Eq | 3.76 | Earnings | 2026/11/3 | SMA50 | 8.99% ($422.44) | Rel Volume | 0.93 | Prev Close | $460.28 |
| Employees | 31500 | LT Debt/Eq | 3.6 | EPS/Sales Surpr. | 11.47% 2.95% | SMA200 | 21.8% ($378.01) | Avg Volume(3M) | 2.78M | Price | $460.42 |
| IPO | 1983/6/17 | Option/Short | Yes/Yes | Trades | 40225 | Volume | 2,579,693 | Change | 0.03% |
💊 A global large-cap pharmaceutical and biotech company focused on biopharmaceuticals and biologics. Founded in California in 1980, it holds a portfolio of blockbuster drugs spanning therapeutic areas such as osteoporosis, immunology, cardiovascular disease, and oncology, and is a representative biotech firm that combines stable cash flow with continued investment in research and development.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded about as much as usual. That is 93% of its average volume.
Ex-dividend date: November 20
11 days to go. Buy before this date to receive the dividend.
AMGN makes money exceptionally well
Of every $100 in sales, $35.60 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.5% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,579. Peers typically go for $1,515. Compared with its own 5-year average, it is 14% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +115.4%. The S&P 500 did +57% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 2.19% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 85.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 21 in the industry
Based on market cap of $249B.
Earnings Analysis · 8/4 Amgen ($AMGN) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat Estimates, Modest After-Hours Gain Investing Guides · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is AMGN?
AMGN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of AMGN?
The market cap of AMGN is approximately $249.0B, ranking 59 within its sector.
Does AMGN pay dividends?
AMGN has a dividend yield of approximately 2.19%, with an annual dividend of $10.07.
What is the P/E ratio of AMGN?
AMGN has a P/E ratio of approximately 26.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AMGN?
AMGN has recorded a 52-week high of $483.99 and a low of $312.39.
